Patents and licences on antiretrovirals: A snapshot

July 2015
UNITAID Secretariat
World Health Organization
Avenue Appia 20
CH-1211 Geneva 27
Switzerland
T +41 22 791 55 03
F +41 22 791 48 90
unitaid@who.int
www.unitaid.eu

Medicines Patent Pool
Chemin Louis-Dunant 17
CH-1202 Geneva 20
Switzerland
T +41 22 533 5055
office@medicinespatentpool.org
www.medicinespatentpool.org

UNITAID is hosted and administered by the World Health Organization

© 2015 World Health Organization
(Acting as the host organization for the Secretariat of UNITAID)

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

This report was prepared by Esteban Burrone and Karin Timmermans. All reasonable precautions have been taken by the authors to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the Medicines Patent Pool, UNITAID or the World Health Organization be liable for damages arising from its use.
CONTENTS

Acronyms and abbreviations .............................................................................................................. iv
Preface .................................................................................................................................................. 1
Structure of the report .......................................................................................................................... 2

1. INTRODUCTION ............................................................................................................................ 3
   1.1. Patents and antiretrovirals .......................................................................................................... 3
   1.2. Patents as territorial rights ......................................................................................................... 3
   1.3. Licensing of patents on antiretrovirals ....................................................................................... 4
   1.4. Patents and fixed-dose combinations ......................................................................................... 5
   1.5. Methodology and data sources ................................................................................................ 5
   1.6. Disclaimers ................................................................................................................................ 5
   1.7. Countries covered ...................................................................................................................... 6

2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL .................................................................... 7
   2.1. Abacavir (ABC) ......................................................................................................................... 7
   2.2. Atazanavir (ATV) ...................................................................................................................... 9
   2.3. Cobicistat (COBI or c) ............................................................................................................. 10
   2.4. Darunavir (DRV) .................................................................................................................... 11
   2.5. Dolutegravir (DTG) ................................................................................................................ 12
   2.6. Efavirenz (EFV) ...................................................................................................................... 13
   2.7. Elvitegravir (EVG) .................................................................................................................. 14
   2.8. Emtricitabine (FTC) ............................................................................................................... 15
   2.9. Etravirine (ETV) ...................................................................................................................... 16
   2.10. Lamivudine (3TC) .................................................................................................................. 17
   2.11. Lopinavir (LPV) ..................................................................................................................... 18
   2.12. Maraviroc (MVC) ................................................................................................................... 19
   2.13. Nevirapine (NVP) .................................................................................................................. 20
   2.14. Raltegravir (RAL) ................................................................................................................... 21
   2.15. Rilpivirine (RPV) ................................................................................................................... 22
   2.16. Ritonavir (RTV or r) .............................................................................................................. 23
   2.17. Tenofovir alafenamide (TAF) ............................................................................................... 24
   2.18. Tenofovir disoproxil fumarate (TDF) .................................................................................... 25
   2.19. Zidovudine (AZT) .................................................................................................................. 26

3. CONCLUSION ................................................................................................................................. 27
Annex I. Summary table on ARV patents and licences ................................................................. 28
Annex II. Overview of patents and licences relating to selected fixed-dose combinations .......... 30
Annex III. Licensing policies by ARV ............................................................................................ 32
### Acronyms and abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>lamivudine</td>
</tr>
<tr>
<td>ABC</td>
<td>abacavir</td>
</tr>
<tr>
<td>AR IPO</td>
<td>African Regional Intellectual Property Organization</td>
</tr>
<tr>
<td>ARV(s)</td>
<td>antiretroviral(s)</td>
</tr>
<tr>
<td>ATV</td>
<td>atazanavir</td>
</tr>
<tr>
<td>AZT</td>
<td>zidovudine</td>
</tr>
<tr>
<td>cobicistat</td>
<td>cobicistat</td>
</tr>
<tr>
<td>COBI</td>
<td>cobicistat</td>
</tr>
<tr>
<td>d4T</td>
<td>stavudine</td>
</tr>
<tr>
<td>DRV</td>
<td>darunavir</td>
</tr>
<tr>
<td>DTG</td>
<td>dolutegravir</td>
</tr>
<tr>
<td>EA PO</td>
<td>Eurasian Patent Office</td>
</tr>
<tr>
<td>EFV</td>
<td>efavirenz</td>
</tr>
<tr>
<td>ETV</td>
<td>etravirine</td>
</tr>
<tr>
<td>EVG</td>
<td>elvitegravir</td>
</tr>
<tr>
<td>FDC(s)</td>
<td>fixed-dose combination(s)</td>
</tr>
<tr>
<td>FTC</td>
<td>emtricitabine</td>
</tr>
<tr>
<td>LPV</td>
<td>lopinavir</td>
</tr>
<tr>
<td>LPR/r</td>
<td>lopinavir/ritonavir fixed-dose combination</td>
</tr>
<tr>
<td>MPP</td>
<td>Medicines Patent Pool</td>
</tr>
<tr>
<td>MVC</td>
<td>maraviroc</td>
</tr>
<tr>
<td>NVP</td>
<td>nevirapine</td>
</tr>
<tr>
<td>r</td>
<td>ritonavir</td>
</tr>
<tr>
<td>RAL</td>
<td>raltegravir</td>
</tr>
<tr>
<td>RPV</td>
<td>rilpivirine</td>
</tr>
<tr>
<td>RTV</td>
<td>ritonavir</td>
</tr>
<tr>
<td>TAF</td>
<td>tenofovir alafenamide</td>
</tr>
<tr>
<td>TDF</td>
<td>tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
PREFACE

We are pleased to present the second edition of the UNITAID–Medicines Patent Pool (MPP) report *Patents and licences on antiretrovirals: A snapshot*. UNITAID founded the MPP in 2010 as part of its efforts to increase access to better and more affordable HIV medicines. As part of our shared mandate to improve health options for people living with the virus in developing countries, both organizations remain strongly committed to enhancing the transparency of the intellectual property status of new and WHO-recommended HIV treatments. Until recently, it was difficult to assess fully the patent landscape of these medicines, especially in high-prevalence countries. Obtaining information was time-consuming, expensive and often required significant legal, technical and linguistic expertise.

The launch of the MPP Patent Status Database in April 2012 greatly improved our understanding of intellectual property challenges to the development and scale-up of important HIV medicines. Today, the database is the single largest repository of patent status information on antiretrovirals in developing countries and it has become an essential guide for international purchasing organizations, generic developers, international organizations and national treatment programmes globally.

In 2014, UNITAID and the MPP published an easy-to-use reference booklet to complement the database. The snapshot report provided a holistic overview of the intellectual property situation for stakeholders working in the field of HIV and access to treatment. Given the interest in last year’s report, as well as the rapidly evolving legal and regulatory environment, we are pleased to present an updated version of the *Patents and licences on antiretrovirals: A snapshot*. We hope that the publication will continue to be of value to a wide range of partners as well as to the public health community at large.

Lelio Marmora  
Executive Director  
UNITAID

Greg Perry  
Executive Director  
Medicines Patent Pool
Structure of the report

The report provides an overview of the patent landscape with respect to a select number of antiretroviral (ARV) medicines in developing countries as of April 2015. The focus is primarily on those ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.

Part 1 provides a brief introduction to patents and licences and their effect on the market for ARVs. It introduces key concepts that will facilitate an understanding of the report. It also explains which data sources were used for the report and notes a number of disclaimers with regard to the information contained in the report.

Part 2 is the core of the report. It outlines the patent status and licensing status of each ARV in 86 countries. For each ARV the report indicates whether that ARV is included in fixed-dose combinations for which there may be patents. General conclusions are drawn in light of the data. The key purpose is to provide an overview of the patent landscape for each ARV and, in particular, to show in which countries market competition for a given ARV is possible in view of existing patents and licences.

Annex I is a summary table that provides a “snapshot” of ARV patents and licences in developing countries. Annex II provides an overview of patents with respect to selected fixed-dose combinations. Annex III summarizes the information that is currently publicly available on existing voluntary licences.
1. INTRODUCTION

1.1. Patents and antiretrovirals
A patent is a form of legal right granted by government to provide exclusivity over a new invention for a limited period of generally 20 years. During that period, the patent holder has the right to exclude others from making, importing, offering for sale, selling or using the patented invention in the country (or countries) in which the patent was granted. Patents can be granted for different types of inventions, including a new medicine such as a new ARV. This section describes briefly how patents on ARVs are granted and introduces some key concepts that are important for understanding Part 2 and the annexes.

To obtain a patent on a new ARV, a pharmaceutical company or research organization must file a patent application at the national patent office of each country in which it would like to obtain exclusivity. Each patent office is then responsible for examining the application and making a decision on whether the invention described in the application fulfils the criteria for patentability. The patent examination process generally takes several years and during that period the patent application is considered to be pending. If the invention is considered to meet the patentability criteria, the patent office grants a patent which confers exclusive rights on the patent holder, thus effectively enabling the patent holder to prevent others from making, selling, importing or using the patented product or process in the country for which the patent was granted. Some patent offices provide opportunities for third parties to submit patent oppositions during a specified period of time. Depending on national laws, this may happen prior to the grant of a patent or after a patent has been granted.

Patents may be granted for new products such as medicines, or for processes for manufacturing those medicines. Product patents may be granted on new molecules (often referred to as “base” patents or “compound” patents), or on specific forms or formulations of medicines (often referred to as “secondary” patents). The latter could include, for example, a particular salt form, an oral solution or tablet formulation of a given medicine, or a fixed-dose combination that combines more than one ARV compound into a single tablet. Some secondary patents (notably those related to liquid dosage forms) are relevant to paediatric formulations of a medicine but do not cover formulations for adults. In practice, new ARVs are generally covered by more than one patent or patent application.

The present report focuses on the compound patents for ARVs and a select number of secondary patents. In certain instances, information on several secondary patents on the same ARV has been combined for the sake of simplicity. This is notably the case for combination products or where there are multiple secondary patents/patent applications on a particular ARV. In such cases, the text and tables indicate whether at least one secondary patent has been granted and, if not, whether at least one application was filed.

1.2. Patents as territorial rights
Patents are territorial rights, which means that they have effect only in the specific territory for which they were granted. Usually the territory is a country, but there are also some regional patent offices that grant patents for a group of countries. This is the case, for instance, of the Organisation Africaine de la Propriété Intellectuelle (OAPI), which grants patents that are valid in 16 countries in Africa. Other regional patent offices that are referred to in this report are the African Regional Intellectual Property Organization (ARIPO) and the Eurasian Patent Office (EAPO). The list of countries covered by these regional patent offices is provided in section 1.7.

---

1 Applicants have 12 months from the date on which they file the first patent application relating to an invention to file the same application in all the countries in which they wish to obtain protection, after which period it is no longer possible to do so. If an international patent application is filed using the Patent Cooperation Treaty administered by WIPO, the 12 months are effectively extended to 30 months.
2 It should be noted that a few patent offices (e.g. as in South Africa) do not undertake substantive examination of patent applications but examine only whether all the formalities have been met.
3 It should also be noted, however, that certain incremental inventions may not be patentable in some countries, as countries have set different thresholds for patentability.
As a result of the territorial nature of patents, an ARV may be patented in some countries but not in others. This may determine, for example, the extent to which there is market competition for a given ARV in different countries.

Despite the territorial nature of patents, it is important to note that the existence of patents on ARVs in the countries where most ARVs are currently manufactured (e.g. Brazil, China, India and South Africa) may be sufficient to ensure exclusivity across developing countries to the patent holders. This is because patents in manufacturing countries could be used to prevent the production – and therefore prevent export – of the patented medicine to other countries. Thus, in order to understand whether there are patents that may have an impact on market competition in a country that imports ARVs, it is often necessary to review the patent status in countries that are likely to manufacture the ARVs as well as in the importing country.

1.3. Licensing of patents on antiretrovirals

During the life of the patent, the patent holder may exercise the right to block others from manufacturing, selling or importing the patented product without consent. However, the patent holder may also give consent to other manufacturers to make or sell the product under certain conditions. This is generally done by means of a “voluntary licence” which sets out the conditions under which consent is given.

Licensing terms and conditions generally specify the countries in which a medicine may be made or sold, whether fixed-dose combinations can be developed, whether royalties are payable to the patent holder, which quality criteria need to be met by the licensee, and a wide range of other provisions that indicate what the licensee may and may not do. Unfortunately, a detailed analysis of voluntary licences is not possible at this stage since, with the exception of the licences negotiated by the Medicines Patent Pool (MPP), the full terms and conditions of licences are usually confidential. Nevertheless, some general conditions are known and are included in this report.

In some cases, the patent holder may announce a commitment not to enforce its patents in certain countries; this may be done through a non-assert declaration, a commitment not to enforce, an immunity-from-suit agreement or similar mechanism. The practical effect of such commitments is often similar to that of licences and is treated in this report as equivalent to licences. Nevertheless, the scope and certainty of these mechanisms varies.

As licences have become relatively common in the HIV field, it is important to look both at the existence of patents on a given ARV and at whether licences are available that cover a given country. Accordingly, this report includes licensing status information for each ARV.

The MPP negotiated some of the licences mentioned in this report. The MPP was established in 2010 with the support of UNITAID to negotiate public-health oriented and transparent voluntary licences on HIV medicines. The MPP’s objective is to enhance access to more affordable HIV treatment in developing countries and to promote the development of new technologies such as fixed-dose combinations and formulations suitable for children.

In addition to voluntary licences, there are also instances in which a government may intervene without the consent of the patent holder and may issue a licence allowing the manufacture or importation of a given medicine despite the existence of a patent. This is called a compulsory licence and is allowed by most national patent laws.

---

1.4. Patents and fixed-dose combinations

The advantages of fixed-dose combinations (FDCs), which combine several ARVs into a single formulation for the treatment of HIV, have been repeatedly highlighted.\(^5\) It is important to note that patents on any individual ARV that is included in an FDC may have an impact on competition for the FDC as a whole. Thus, for an ARV manufacturer to be able to manufacture a given FDC and supply it to a given country, the manufacturer would need to ensure that in the countries of manufacture and sale there are no blocking patents on any of the ARVs included in the FDC or, if there are such patents, that the manufacturer has the necessary licences to do so.

In some instances, there are also patents on the FDCs themselves – e.g. on the combination of tenofovir disoproxil fumarate (TDF) with emtricitabine (FTC), or abacavir (ABC) with lamivudine (3TC). These “combination patents” must be taken into consideration when analysing the patent landscape of a given treatment regimen. Annex II provides an overview of the patent and licence status of selected FDCs.

1.5. Methodology and data sources

The original version of this report was prepared by Esteban Burrone of the Medicines Patent Pool and Karin Timmermans of UNITAID, with input from Sandeep Juneja, Chan Park, Carmen Perez-Casas and Greg Perry. Pascale Boulet, Claire Willmington and Esteban Burrone updated the report for this second edition.

The main source of patent data for this report is the Patent Status Database for Selected HIV Medicines developed by the MPP. Covering 24 ARVs in 89 countries, the MPP Patent Status database is the most comprehensive source of patent status data on ARVs available today. The database includes information collected from national and regional patent offices, primarily in low- and middle-income countries. Some of the countries included in the database have since become high-income countries according to World Bank classifications and have therefore not been included in this report which focuses on low- and middle-income countries.

Information on voluntary licences on ARVs was obtained from pharmaceutical company press releases and other public communications issued by the companies, or from the licences negotiated by the MPP. As noted above, however, public information on voluntary licences not involving MPP is very limited.

1.6. Disclaimers

While the database used as the basis for this report is the most complete source of patent status data from developing countries, it is important to bear in mind its limitations. The database focuses on a select number of patents per ARV, and this may not be a comprehensive list – i.e. there may be other relevant patents that have not been identified and which therefore are not mentioned in this report.

Moreover, while the database is regularly updated, the patent status of a given ARV in a given country can change and data may therefore become outdated. It is advisable always to consult with the national or regional patent office for the most-up-to-date information on the status of a given patent or patent application.

With respect to expiry dates of the different ARVs, it is assumed in this report that patents expire in most countries 20 years after the filing of the patent application. It should be noted, however, that the exact date of expiry may vary from country to country as a result of differences in national patent laws or the existence of patent term extensions which are possible in some countries.

Lastly, the database includes information on 89 (primarily low- and middle-income) countries where more than 85% of people living with HIV reside but it does not include all countries since data were not available to the MPP. A list of the countries covered by this report is provided below (section 1.7).

---

As concerns voluntary licences, the report is limited to the information that has been made publicly available by the licensors concerned, and may therefore be incomplete.

With respect to compulsory licences, in addition to those that have been widely publicized there are instances in which countries have issued letters to procurement agencies indicating that a medicine may be imported for the purpose of supplying the ministry of health, despite the existence of patents on the medicine. While some of these instances have been reported elsewhere, there is a lack of publicly available information on this practice. Therefore, it has not been possible to include them in this report.

### 1.7. Countries covered

The following countries are covered by this report: Albania, Algeria, Argentina, ARIPO member countries, Bolivia, Bosnia and Herzegovina, Brazil, China, Colombia, Costa Rica, Cuba, Dominican Republic, EAPO member countries, Ecuador, Egypt, El Salvador, Georgia, Guatemala, Honduras, India, Indonesia, Jordan, Malaysia, Mexico, Mongolia, Montenegro, Morocco, Nicaragua, Nigeria, OAPI member countries, Pakistan, Panama, Paraguay, Peru, Philippines, South Africa, Sri Lanka, Thailand, Tunisia, Turkey, Ukraine, Uzbekistan, Venezuela and Viet Nam.

ARIP member countries are: Botswana, Gambia, Ghana, Kenya, Lesotho, Liberia, Malawi, Mozambique, Namibia, Rwanda, Sao Tome and Principe, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe.

EAPO member countries are: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Republic of Moldova, Russian Federation (not included in the report), Tajikistan and Turkmenistan.

OAPI member countries are: Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Côte d’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Senegal and Togo.

---

6 "Hoen E. The global politics of pharmaceutical monopoly power. Diemen: AMB Publishers; 2009."
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.1. Abacavir (ABC)

Abacavir is recommended by WHO as a component of first- and second-line treatment regimens for infants and children.

Patent status

The compound patent on abacavir expired in 2010 in all jurisdictions for which recent data are available. There are, however, other patents on forms and formulations of abacavir that may affect the market for abacavir and abacavir-containing formulations.

A patent on the hemisulfate salt is expected to expire in 2018. According to available information, the patent was granted in Algeria, Argentina, ARIPO member countries, China, EAPO member countries, Ecuador, Egypt, El Salvador, Georgia, Guatemala, Honduras, Indonesia, Jordan, Malaysia, Mexico, Morocco, Nicaragua, Nigeria, OAPI member countries, Pakistan, Panama, Peru, Philippines, South Africa, Sri Lanka, Tunisia, Turkey and Ukraine, and is pending in Brazil and Thailand.

A patent on the paediatric oral solution, which is expected to expire in 2019, was granted in Algeria, Argentina, ARIPO member countries, Colombia, Dominican Republic, EAPO member countries, Guatemala, Honduras, India, Indonesia, Malaysia, Morocco, Mexico, Nicaragua, Pakistan, Panama, Peru, Philippines, South Africa, Sri Lanka, Thailand, Tunisia and Turkey, and is pending in Egypt.

Licensing status

The patent holder has committed to licensing abacavir to interested ARV manufacturers for all low-income countries, least-developed countries and sub-Saharan Africa (representing at the time of announcement 69 countries).

In February 2013, patents on paediatric formulations of abacavir and its combination with lamivudine (3TC) for paediatric use have been licensed to the MPP with a geographical coverage of 118 countries. In November 2014, the geographical scope was extended to 121 countries by including Peru, Ukraine and Venezuela. The licence also allows sale in other countries where there are no patents in force.7 In addition, a licence on abacavir paediatric formulations has been granted by the patent holder directly to at least one manufacturer with a more limited geographical scope.

In the context of the MPP licence on dolutegravir (DTG), licensees benefit from a covenant not to sue for formulations containing ABC and DTG for countries covered by the DTG licence.

In 2012, Indonesia issued a compulsory licence on abacavir and Ecuador issued a compulsory licence on the combination patent referred to below.

Combinations

Combinations of abacavir have been developed with lamivudine, and with lamivudine and zidovudine, and are sold by several generic manufacturers. Patents on the combination(s) exist in several jurisdictions, including ARIPO member countries, Brazil, China, EAPO member countries, Georgia, Malaysia, Mexico, OAPI member countries, Pakistan, Philippines, South Africa, Thailand, Turkey and Uzbekistan, and are pending in Sri Lanka.

A more recent combination of abacavir with lamivudine and dolutegravir received regulatory approval in the European Union and USA in 2014; patents on this combination are pending or granted in several jurisdictions.

---

7 The full text of the licence is available on the Medicines Patent Pool website at www.medicinespatentpool.org.
Conclusion
While the compound patent for abacavir has expired, patents on the hemisulfate salt, the paediatric formulation and the combination of abacavir with lamivudine have been widely granted in many jurisdictions and could limit market competition for abacavir in certain countries not covered by the voluntary licences.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.2. Atazanavir (ATV)
Atazanavir (boosted with ritonavir) is recommended by WHO as a component of second-line treatment regimens in adults.

**Patent status**
The compound patent on atazanavir is exclusively licensed to Bristol-Myers Squibb by Novartis. Its expected expiry date is 2017. According to available information, the compound patent is currently in force in the following low- or middle-income countries: Argentina, Brazil, China, Malaysia, Mexico, Pakistan, Philippines and South Africa. The patent application is pending in India and Thailand.

The patent on the bisulfate salt is also relevant to the production of atazanavir. Its expected expiry date is 2018 and it has been granted in the following low- or middle-income countries: Argentina, China, Egypt, Georgia, Indonesia, Malaysia, Mexico, Pakistan, Peru, Philippines, South Africa, Thailand, Turkey and Ukraine.

**Licensing status**
In December 2013, atazanavir was licensed to the MPP. The licence has a geographical scope of 110 countries and contains provisions that do not impede sale to additional countries where there is no infringement of patents on atazanavir under certain circumstances. The licence has so far been sublicensed to four companies. Prior to the licence agreement with the MPP, immunity from suit agreements were in place with three generic manufacturers with a geographical scope comprising sub-Saharan Africa and India (50 countries).

A bilateral technology transfer agreement has been signed between the patent holder and a Brazilian company with a licence for production and sale in Brazil.

**Combinations**
There are two fixed-dose combinations containing atazanavir that currently have regulatory approval: atazanavir/ritonavir (ATV/r), for which there are currently two quality-assured manufacturers, and atazanavir/cobicistad (ATV/c), currently available only from the originator company.

**Conclusion**
Market competition for atazanavir is likely to increase in countries covered by the MPP licence or in countries where there are no patents in force. In countries outside the scope of the MPP licence and in which there are patents on atazanavir, market competition may be delayed until patent expiry. Patents on ritonavir will also probably affect the sale of ATV/r in certain jurisdictions.

---

8 The full text of the licence is available on the Medicines Patent Pool website at www.medicinespatentpool.org.
2.3. Cobicistat (COBI or c)
Cobicistat was approved by the United States Food and Drug Administration as a stand-alone pharmacokinetic booster in 2014 and has also been approved in combination with other ARVs.

Patent status
The compound patent on cobicistat is expected to expire in 2027 or 2028. It has been granted in ARIPOMember countries, China, EAPO member countries, Mexico, OAPI member countries and in Ukraine. It is pending in Argentina, Brazil, India, Indonesia, South Africa, Thailand and Viet Nam. Other patents on cobicistat are also pending in these countries and perhaps elsewhere. However, there is limited information on the status of these other patents in developing countries.

Licensing status
Voluntary licences on cobicistat have been granted in relation to 112 countries (nine of them on a semi-exclusive basis to three different companies). The licence granted to the MPP covers 103 countries and has so far been sublicensed to eight companies.9

Combinations
The following combinations of cobicistat have been developed: TDF/FTC/EVG/COBI, ATV/c and DRV/c, and the following are currently under development: TAF/FTC/EVG/COBI and TAF/FTC/DRV/COBI.

Conclusion
While no generics are yet on the market, competition for this product is likely to occur in countries covered by the voluntary licences.

---

9 The full text of the licence is available on the Medicines Patent Pool website at www.medicinespatentpool.org.
2.4. Darunavir (DRV)
Darunavir (boosted with ritonavir) is recommended by WHO as a component of third-line treatment regimens and as an alternative in second-line regimens for adults.

**Patent status**
The [compound patent](#) on darunavir generally expired in August 2013 in jurisdictions in which it had been granted.

A [method of use patent](#) is not in force in developing countries.

[Patents on the pseudopolymorph](#) and/or on the [combination with ritonavir](#) have been granted in Albania, ARIPO member countries, China, EAPO member countries, Indonesia, Mexico, Philippines, South Africa and Turkey, and are pending in Brazil, India, OAPI member states and Viet Nam.

**Licensing status**
A commitment not to enforce patents on darunavir in sub-Saharan Africa and least-developed countries has been announced by the patent holder. The commitment was extended to 128 countries for paediatric products in 2015. In addition, a licence was granted to one manufacturer for the sale of darunavir in India.

**Combinations**
Darunavir requires boosting with ritonavir or cobicistat. While no combination with ritonavir has yet received regulatory approval, the combination with cobicistat was registered by the European Medicines Agency (EMA) in November 2014 and by the United States Food and Drug Administration (USFDA) in January 2015. Clinical trials are ongoing for the combination DRV/TAF/FTC/CObI.

**Conclusion**
There appear to be limited patents on darunavir in most developing countries. The compound patent has expired. Secondary patents, such as those on the pseudopolymorph or on combinations, may potentially delay competition in certain countries that are not covered by the commitment not to enforce patents. Patents on ritonavir or cobicistat would also affect the sale of DRV/r or DRV/c in certain jurisdictions.
2.5. Dolutegravir (DTG)

Dolutegravir was approved by the United States Food and Drug Administration in 2013.

**Patent status**

The compound patent for dolutegravir is expected to expire in 2026. The patent has been granted in Algeria, China, Colombia, EAPO member countries, Indonesia, Mexico, Morocco, Philippines, South Africa, Turkey and Ukraine, and is pending in Brazil, Egypt, India, Malaysia, Nigeria and Viet Nam.

**Licensing status**

In April 2014, dolutegravir was licensed to the MPP (through separate licences for adult and paediatric formulations). The paediatric licence includes 121 countries. The adult licence includes all countries in sub-Saharan Africa, least-developed countries, low-income countries, Egypt, India, Indonesia, Philippines, Turkmenistan and Viet Nam. In addition, the licences allow for the sale of generic versions of dolutegravir outside the licensed countries where there are no patents in force. The licence granted to MPP has been sublicensed to nine companies.

**Combinations**

A combination containing DTG + ABC/3TC, has received regulatory approval. In addition to the patents on dolutegravir and abacavir, patents on the combinations ABC/3TC and ABC/3TC/DTG may have an impact on the use of a regimen consisting of ABC/3TC and DTG. The combination patent on ABC/3TC/DTG, which is expected to expire in 2031, has been granted in Colombia, Mexico, Mongolia and South Africa, and is pending in Albania, Algeria, ARIPO member countries, EAPO member countries, China, Costa Rica, Dominican Republic, Ecuador, Egypt, India, Indonesia, Malaysia, Morocco, Nigeria, Peru, Philippines, Thailand, Tunisia, Ukraine and Viet Nam. The MPP licence on dolutegravir also covers combinations containing abacavir and dolutegravir with the same geographical scope.

**Conclusion**

Following the licence between the MPP and ViiV Healthcare, market competition for dolutegravir is likely to take place in countries covered by the licence as well as in those countries in which dolutegravir is not patented.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.6. Efavirenz (EFV)
Efavirenz is recommended by WHO as a component of first-line treatment regimens for adults and as a component of first- and second-line treatment regimens for children over 3 years of age.

Patent status
The compound patent on efavirenz expired in or around August 2013 in most countries. There are some exceptions where it is expected to expire later as a result of patent term extensions (for instance, expiry in Ukraine is expected in 2018). According to available information, this patent remains in force in Argentina (process patent only), Dominican Republic, and Ukraine (patent extension beyond 20 years).

Licensing status
A number of South African manufacturers have obtained a licence for production of efavirenz in South Africa and sale to 10 neighbouring countries. Compulsory licences on efavirenz have been issued in Brazil, Indonesia and Thailand.

Combinations
Combinations of efavirenz with TDF/FTC and with TDF/3TC have been developed and are recommended by WHO as preferred first-line regimens. Bristol-Myers Squibb and Gilead Sciences jointly own patents, and patent applications on the combination of EFV with TDF/FTC, which have been granted in China, EAPO member states, Mexico, South Africa and Turkey, are also pending in Argentina, Brazil, India and Venezuela. The MPP licence on TDF includes a covenant not to sue which covers this combination for the 112 countries included in the licence.

Conclusion
The compound patent on efavirenz was in force in several countries and has expired in the majority of them in 2013. Several quality-assured generics are on the market and, with few exceptions, there should in principle be no intellectual property-related constraints to market competition for efavirenz as a single agent. Patents and patent applications on TDF/FTC/EFV may delay market competition for this combination in countries not included in the licence (see Annex II).
2.7. Elvitegravir (EVG)
Elvitegravir was approved by the United States Food and Drug Administration in 2012 in the context of the approval of the combination TDF/FTC/EVG/COBI (also known as the Quad).

**Patent status**
The compound patent on elvitegravir is expected to expire in 2023 and was granted in Albania, Argentina, Brazil, China, Colombia, India, Indonesia, Malaysia, Mexico, Nigeria, Peru, Philippines and South Africa. It is pending in Thailand, Venezuela and Viet Nam.

The patent on the crystal form is granted in China, Colombia, Malaysia, Mexico, Peru, Philippines and South Africa, and is pending in Argentina, Bolivia, Brazil, Thailand and Venezuela.

**Licensing status**
Voluntary licences on elvitegravir have been granted in relation to 109 countries (nine of them on a semi-exclusive basis to three companies). The licence granted to the MPP covers 100 countries and has so far been sublicensed to eight companies.10

**Combination**
Elvitegravir has been developed in combination with TDF, FTC and COBI.

**Conclusion**
While no generics are yet on the market, several manufacturers are developing elvitegravir. Once quality-assured versions are available, competition is likely to take place in the countries covered by the voluntary licences.

---

10 The full text of the licence is available on the Medicines Patent Pool website at www.medicinespatentpool.org.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.8. Emtricitabine (FTC)
Emtricitabine is recommended by WHO as a component of first-line treatment regimens and as an alternative in second-line regimens for adults. It is also an alternative component in first- and second-line regimens for children. It is generally considered to be interchangeable with lamivudine.\textsuperscript{11}

Patent status
The compound patent on emtricitabine expired in 2010. Other patents have also expired and are therefore no longer in force in most developing countries. However, patents on combinations containing emtricitabine remain in force in many jurisdictions.

Licensing status
The patent holder has issued “covenants not to sue” on emtricitabine with a geographical scope of 112 countries. The covenant not to sue granted through the MPP is publicly available.\textsuperscript{12}

Combinations
The following fixed-dose combinations include emtricitabine: TDF/FTC, TDF/FTC/EFV, TDF/FTC/RPV and TDF/FTC/EVG/COBI. Patents and patent applications on some of these combinations have been filed (and in a few cases granted) in several developing countries (see Annex II).

Conclusion
Given the expiry of the compound patent on emtricitabine, and covenants not to sue that cover certain secondary patents, there is already strong market competition for ARV regimens containing emtricitabine. Nevertheless, patents on the combinations (or on any of the other individual ARVs in those combinations) may delay market competition for the combinations containing emtricitabine in countries not covered by the licences.


\textsuperscript{12} The full text of the covenant not to sue is available on the Medicines Patent Pool website at www.medicinespatentpool.org.
2.9. Etravirine (ETV)
Etravirine is recommended by WHO as a component of third-line treatment regimens.

Patent status
The compound patent on etravirine is expected to expire in 2019. It has been granted in Argentina, ARIPO member countries, Brazil, China, EAPO member countries, India, Indonesia Malaysia, Mexico, OAPI member countries, Philippines, South Africa, Sri Lanka, Thailand, Turkey, Ukraine and Viet Nam, and appears to be pending in Pakistan.

Patents on solid formulations of etravirine, expiring in 2020, have been granted in ARIPO member countries, China, EAPO member countries, India, Indonesia, Mexico, OAPI member countries, South Arica and Ukraine, and are pending in Brazil, Turkey and Viet Nam.

Licensing status
There are currently no voluntary licences for the manufacturing of generic etravirine. There is a distribution and packaging agreement with one company for sub-Saharan Africa.

Combinations
There are no fixed-dose combinations containing etravirine on the market.

Conclusion
There are no pharmaceutical companies manufacturing generic etravirine and, given the patent coverage in key manufacturing countries, it is likely that a licence would be required for that to happen. Etravirine is widely patented in developing countries.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.10. Lamivudine (3TC)
Lamivudine is recommended by WHO as a component of all first- and second-line treatment regimens. It is generally considered interchangeable with emtricitabine.13

Patent status
The compound patent on lamivudine expired in 2010. Other patents on lamivudine, while granted in many developing country jurisdictions, do not appear to affect competition for lamivudine in the market.

Licensing status
In 2010, the patent holder announced the intention to license all of its current and pipeline products with a geographical scope that includes sub-Saharan Africa, least-developed countries and low-income countries (69 countries in total). Nevertheless, given the expiry of the key patents on this ARV, licences appear to be no longer required by ARV manufacturers wishing to sell generic versions in most (if not all) developing-country jurisdictions.

A licence on the combination of abacavir and lamivudine for paediatric use was granted to the MPP in February 2013 and covers 121 countries.

Combinations
There are several combinations of lamivudine that have received regulatory approval, many of which are recommended by WHO. These include ABC/3TC, ABC/3TC/AZT, TDF/3TC, TDF/3TC/EFV and ABC/3TC/DTG. Patents on the ABC/3TC combination have been granted in several jurisdictions, including ARipo member countries, Brazil, China, EApo member countries, Georgia, Malaysia, Mexico, Oapi member countries, Pakistan, Philippines, South Africa, Thailand, Turkey and Uzbekistan, and are pending in Sri Lanka

Conclusion
Market competition for lamivudine, and for most fixed-dose combinations containing lamivudine, is strong with several manufacturers having quality-assured formulations. Combination patents have been granted in some countries and may delay market competition for those combinations.

2.11. Lopinavir (LPV)

Lopinavir (boosted with ritonavir, LPV/r) is recommended by WHO as a component of second-line treatment regimens for adults and children, and as a component of the first-line treatment regimen for children under 3 years of age.

Patent status

The compound patent for lopinavir is expected to expire in 2016 and has been granted in Argentina, Brazil, China, Colombia, Mexico, Pakistan, Philippines, South Africa and Thailand.

Since lopinavir is available only in combination with ritonavir, patents on formulations of lopinavir/ritonavir are also very important and are outlined under “Combinations” below.

Licensing

In December 2014, certain paediatric formulations of LPV/r and ritonavir were licensed to the MPP. The licence includes 102 countries and allows for the sale of generic versions of LPV/r outside the licensed territory to countries where there are no patents in force. The licence is primarily on paediatric formulations suitable for children under 3 years of age.

Some countries (e.g. Ecuador) have issued compulsory licences on ritonavir or on the combination of lopinavir with ritonavir (e.g. Indonesia and Thailand).

Combinations

A patent on the LPV/r soft gel capsules, expiring in 2017, was granted in Argentina, Brazil, China, Malaysia, Mexico, Philippines, South Africa and Turkey, and is pending in Pakistan and Thailand.

Two patents on LPV/r tablet formulations, which expire in 2024 and 2026 respectively, have been granted in Albania, Bosnia, China, EAPO member countries, Georgia, Guatemala, Indonesia, Malaysia, Mexico, Montenegro, Panama, Peru, Philippines, South Africa, Sri Lanka, Turkey, Ukraine and Viet Nam, and are pending in Brazil, Dominican Republic, Ecuador, El Salvador, Nicaragua and Thailand.

LPV/r is also available as an oral solution and as pellets, both of which are for paediatric use.

Conclusion

Patents on lopinavir, ritonavir and on the capsules and tablets of LPV/r have been granted or are pending in many jurisdictions. There are currently four quality-assured generic suppliers of LPV/r adult formulations and two of paediatric formulations. Competition among manufacturers for adult formulations may be limited to countries where there are no patents or where a compulsory licence has been issued. As for paediatric formulations, market competition (or market entry by generics with new formulations) is likely to take place in countries covered by the MPP licence or in countries where there are no patents in force.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.12. Maraviroc (MVC)

Maraviroc was approved by the United States Food and Drug Administration in 2007. It is not currently recommended by WHO.

Patent status

The compound patent on maraviroc is expected to expire in 2019 in most jurisdictions. It has been granted in Albania, Argentina, ARIPo member countries, Bolivia, Cuba, EAPO member countries, Ecuador, Egypt, Georgia, Guatemala, India, Indonesia, Malaysia, Mexico, Montenegro, Morocco, OAPI member countries, Panama, Peru, Philippines, South Africa, Tunisia, Turkey, Ukraine, Uzbekistan and Viet Nam. According to the latest available data, the patent is also pending in Algeria, Bosnia, Costa Rica, Paraguay and Sri Lanka.

The patent on the crystal form of maraviroc, which is expected to expire in 2021, has been granted in Albania, Argentina, ARIPo member countries, Bosnia, China, Colombia, Cuba, EAPO member countries, Egypt, Georgia, Guatemala, India, Mexico, Mongolia, Montenegro, Morocco, OAPI member countries, Panama, Peru, Philippines, South Africa, Thailand, Tunisia, Turkey, Ukraine and Uzbekistan. The patent is also pending in Bolivia, Brazil, Costa Rica, Nicaragua and Viet Nam.

Licensing status

In July 2010, the patent holder announced the intention to license all its current and pipeline products with a geographical scope of all sub-Saharan Africa, low-income countries and least-developed countries (at the time 69 countries). However, no specific licences on maraviroc have been announced to date and there are no generic products on the market as yet.

Combinations

There are currently no fixed-dose combinations containing maraviroc.

Conclusion

Maraviroc is very widely patented in developing countries and there is currently no generic on the market. If it were included in treatment recommendations and demand were to increase, market competition for maraviroc would probably be limited to the countries for which a commitment to license has been announced.
2.13. Nevirapine (NVP)

Nevirapine is recommended by WHO as a component of alternative first-line treatment regimens for adults, and as a component of alternative first- and second-line treatment regimens for children and infants.

Patent status

The compound patent on nevirapine expired in 2010 in most (if not all) jurisdictions. The patent on the hemihydrate formulation used for children is expected to expire in 2018. It has been granted in Belarus, Brazil, China, Indonesia, Malaysia, Mexico, Montenegro, Peru, Philippines, South Africa, Turkey, Ukraine, Uzbekistan and Viet Nam. On the basis of available information, the patent appears to be pending in Egypt, Pakistan and Thailand, and was rejected in India following a patent opposition.

The patent on the extended release formulation, due to expire in 2028, was granted in Algeria, China, EAPO member countries, Indonesia, Morocco, South Africa, Tunisia and Ukraine. It appears to be pending in Albania, Argentina, Bosnia, Brazil, Ecuador, Egypt, India, Malaysia, Mexico, Pakistan, Philippines, Thailand, Turkey, Venezuela and Viet Nam.

Licensing status

The patent holder has a policy of issuing non-assert declarations for some 78 countries to any manufacturer that obtains WHO prequalification for nevirapine. This covers India, all of Africa, low-income countries and least-developed countries.

Combinations

Nevirapine has been developed in combination with AZT/3TC and d4T/3TC. No patents have been identified on these combinations.

Conclusion

With the compound patent on nevirapine having expired, patents do not appear to be a constraint on market competition for nevirapine in developing countries. In light of existing patents on the paediatric formulation and the extended release formulation, there may be restrictions on competition for these specific formulations outside the countries covered by the non-assert declarations.
2.14. Raltegravir (RAL)

Raltegravir is recommended by WHO as a component of third-line treatment regimens.

**Patent status**

The compound patent on raltegravir is expected to expire in developing countries in or around 2022. According to available information, the patent was granted in Albania, Belarus, China, Colombia, Georgia, India, Indonesia, Kazakhstan, Mexico, Montenegro, Philippines, South Africa, Turkey, Ukraine, Uzbekistan and Viet Nam, and is pending in Brazil.

The patent on the potassium salt is expected to expire in 2025 and was granted in Belarus, China, Colombia, Georgia, Kazakhstan, Indonesia, Malaysia, Mexico, Mongolia, Morocco, Nicaragua, Pakistan, Philippines, South Africa, Tunisia, Turkey, Ukraine and Viet Nam. Patent applications appear to be pending in Albania, Bosnia, Brazil, Ecuador, Egypt, India, Thailand and Tunisia.

**Licensing status**

The patent holder has granted voluntary licences on raltegravir to two manufacturers. Detailed terms and conditions of the licences are not publicly available but the licences are known to cover sub-Saharan African and low-income countries (a total of approximately 58 countries). A bilateral technology transfer agreement has been signed between the patent holder and a Brazilian company with a licence for Brazil.

In February 2015, raltegravir was licensed to the MPP for paediatric formulations. The licence covers 92 countries where 98% of children with HIV live. The licence will facilitate the development of improved child-friendly formulations of raltegravir, which were identified as a priority by WHO.

**Combinations**

Raltegravir is available in combination with lamivudine from the originator. There are no quality-assured generics of this combination as yet.

**Conclusion**

Raltegravir is widely patented in developing countries, including in major countries of manufacture of quality-assured ARVs (e.g. India). If and when manufacturers develop generic versions of the product, their ability to supply them would probably be limited to the countries covered by licences.
2.15. Ilapivirine (RPV)

Ilapivirine was approved by the United States Food and Drug Administration in 2011. It is not currently included in the WHO guidelines.

**Patent status**

The **compound patent** on ilapivirine is expected to expire in 2022. The patent has been granted in Albania, Argentina, ARIPO member countries, China, EAPO member countries, Egypt, India, Indonesia, Mexico, OAPI member countries, Panama, Philippines, South Africa, Sri Lanka, Turkey and Ukraine, and appears to be pending in Brazil, Jordan, Malaysia, Pakistan, Thailand, Venezuela and Viet Nam.

A **patent on the salt form**, expiring in 2025, has been granted in ARIPO member countries, EAPO member countries, Indonesia, Mexico, Philippines, South Africa, Turkey and Ukraine, and is pending in Brazil, China, Ecuador and Viet Nam.

**Licensing status**

Voluntary licences for RPV have been granted to five manufacturers covering 112 countries. The detailed terms and conditions are not publicly available.

**Combinations**

A combination of ilapivirine with TDF/FTC was developed and obtained regulatory approval in 2011. Clinical trials are ongoing for other combinations containing RPV and for a long-acting formulation.

**Conclusion**

While no quality-assured generics are on the market as yet, market competition for this ARV will be possible in the countries covered by the voluntary licence.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.16. Ritonavir (RTV or r)

Ritonavir is recommended by WHO as a booster for atazanavir, lopinavir and darunavir.

Patent status

The compound patent on ritonavir was due to expire at the end of 2013. It is unclear if it is still in force in Brazil and Mexico. Nevertheless, there are other patents that are also relevant to the production and sale of ritonavir.

A patent on the polymorph, which expires in 2019, has been granted in Argentina, China, Indonesia, Malaysia, Mexico, Philippines and Turkey. It is pending in Thailand.

A patent on the tablet formulation, expiring in 2024, was granted in Albania, Bosnia, China EAPO member countries, Indonesia, Mexico, Montenegro, South Africa, Sri Lanka, Turkey, Ukraine and Viet Nam, and appears to be pending in Brazil, Ecuador and Nicaragua.

Licensing

In December 2014, certain paediatric formulations of LPV/r and ritonavir were licensed to the MPP. The licence includes 102 countries and allows for the sale of generic versions of ritonavir outside the licensed countries where there are no patents in force.

Compulsory licences were granted on ritonavir or its combination with lopinavir in Ecuador, Indonesia and Thailand.

Combinations

Currently available combinations that include ritonavir are LPV/r and ATV/r. Patents on ritonavir and on LPV/r tablets are likely to delay competition in certain markets (see under lopinavir).

Conclusion

Since ritonavir has not been patented in key producing countries such as India, there are several generic suppliers of ritonavir on its own or in combination with protease inhibitors. Competition among manufacturers for the adult formulations of ritonavir (alone or in combination) may be limited to countries where there are no patents or where a compulsory licence has been issued. As for paediatric formulations for children under 3 years of age, market competition (or market entry by generics with new formulations) is likely to take place in countries covered by the MPP licence or in countries where there are no patents in force.
2.17. Tenofovir alafenamide (TAF)
Tenofovir alafenamide is a pro-drug of tenofovir, which has been submitted for regulatory approval in combination with emtricitabine (FTC) and as part of a single-tablet regimen comprising TAF/FTC/EVG/COBI.

Patent status
The compound patent on tenofovir was filed by the Czech Academy of Science in 1985 and has expired in most (if not all) jurisdictions where it was granted.

The patent on this tenofovir pro-drug is expected to expire in 2021. The patent has been granted in ARIPO member countries, China, India, Indonesia, Mexico, OAPI member countries, South Africa, Ukraine and Viet Nam and, according to the information that is currently available, is pending in Albania, Brazil and Turkey.

Licensing status
In July 2014, tenofovir alafenamide was licensed to the MPP. The licence covers 112 countries. Separately, bilateral agreements were also announced with two manufacturers. Several generic manufacturers are currently working on the development of TAF.

Combinations
Tenofovir alafenamide has been developed (and has been filed for regulatory approval) in combination with emtricitabine (FTC) and as part of a single tablet regimen comprising TAF/FTC/EVG/COBI. A combination with FTC/DRV/COBI is also under development.

Conclusion
Patents on tenofovir alafenamide have been granted in many of the countries currently producing quality-assured ARVs (e.g. China, India, South Africa) and are pending in others (e.g. Brazil). If and when tenofovir alafenamide is approved, market competition for TAF is likely to occur in countries covered by the licences.
2. OVERVIEW OF PATENTS BY ANTIRETROVIRAL

2.18. Tenofovir disoproxil fumarate (TDF)

Tenofovir disoproxil fumarate is recommended by WHO as a component of the first-line treatment regimen and as an alternative component of second-line regimens for adults. It is also recommended as a component of alternative first-line and second-line treatment regimens for children over 3 years of age.

Patent status

The compound patent on tenofovir was filed by the Czech Academy of Science in 1985 and has expired in most (if not all) jurisdictions where it was granted.

The patents on the disoproxil ester and the fumarate salt are due to expire in 2017 and 2018 respectively. On the basis of available information, these patents have been granted only in China, Indonesia and Mexico and were either not filed or were rejected in most other low- or middle-income countries. A process patent has been granted in India.

Licensing status

Tenofovir disoproxil fumarate has been licensed to several ARV manufacturers with a geographical scope of 112 countries. In 2011, it was licensed to the MPP and the detailed terms and conditions of that licence are publicly available. As a result of the unbundling provisions in the MPP/Gilead licence, generic manufacturers that have taken the MPP licence and made use of that flexibility have been able to supply additional developing countries in which tenofovir disoproxil fumarate is not patented.14

Indonesia issued a compulsory licence on tenofovir and its combinations with FTC and FTC/EFV in 2012.

Combinations

There are several approved combinations that contain tenofovir, such as TDF/FTC, TDF/3TC, TDF/3TC/EFV, TDF/FTC/EFV and TDF/FTC/RPV. Patent applications relating to one or more of these combinations have been granted in ARIPO member states, China, EAPO member states, Indonesia, Mexico, OAPI member states, Philippines, South Africa, Turkey, Ukraine and Viet Nam, and are pending in Argentina, Brazil, India, Malaysia, OAPI member states, Thailand and Venezuela. While licences or “covenants not to sue” on TDF, FTC, TDF/FTC, TDF/FTC/EFV and RPV cover 112 countries, the sale of generic versions of the combinations may be delayed outside those countries as a result of patents on the individual compounds or on the combinations (see Annex II).

Conclusion

With limited exceptions (notably China and Mexico) there appears to be robust market competition for tenofovir today in most low- and middle-income countries. Market competition may be limited for some generic TDF-containing combinations in countries outside the 112 licensed territories.

---

14 The full text of the licence is available on the Medicines Patent Pool website at www.medicinespatentpool.org.
2.19. Zidovudine (AZT)

Zidovudine is recommended by WHO as a component of the second-line treatment regimen for adults and first-line treatment regimens for children less than 3 years of age. It is also a component of alternative first-line treatment regimens for all age groups.

Patent status

The **compound patent** on zidovudine expired in 2006. A patent on the combination with lamivudine expired in 2012 and the patent on the zidovudine/lamivudine tablet formulation was withdrawn or allowed to lapse in most (if not all) developing countries for which recent data are available.

Licensing status

The patent holder has committed to licensing all its ARVs to interested manufacturers for a geographical coverage of 69 countries, including all low-income countries, least-developed countries and sub-Saharan Africa. Nevertheless, given the expiry and withdrawal of most of the patents on this ARV, licences are no longer required by ARV manufacturers to sell generic versions in most (if not all) developing countries.

Combinations

Zidovudine is available as a combination with lamivudine and with 3TC/NVP. As noted above, the key patents on the combination have either expired or appear to have been withdrawn.

Conclusion

As zidovudine was the first ARV to obtain regulatory approval, the main patents have by now expired or have been withdrawn by the patent holder. Market competition for zidovudine, and for combinations that contain zidovudine, is strong with several manufacturers having quality-assured versions.
3. CONCLUSION

As can be seen from the preceding analysis, older ARVs such as zidovudine, emtricitabine, lamivudine and nevirapine are generally off patent. The main patents for these products, where they had been granted, have now generally expired or are close to expiry. Markets for these products tend to be competitive and there are several quality-assured manufacturers that are in a position to supply most (if not all) developing-country markets. Nevertheless, patents or patent applications on some formulations or fixed-dose combinations with other ARVs (e.g. TDF/FTC/EFV or ABC/3TC) may exist in certain countries and could delay competition in countries for which licences are not currently available.

Newer ARVs, including those that are currently in the development pipeline, tend to be more widely patented in developing countries, though there is wide variation between ARVs. Patents on some of these ARVs (such as atazanavir, dolutegravir, elvitegravir, etravirine, lopinavir/ritonavir, raltegravir and rilpivirine) have been filed in a significant number of developing countries and, where they have been granted, are likely to remain in force for several years before they expire. For such ARVs, it is likely that market competition will take place only in countries where there is no patent or where licences have been issued. In addition, the conditions in voluntary licences can vary significantly and may determine whether and where generic ARV manufacturers are able to supply. In light of the above, the likelihood of competition is very country- and product-specific.

From the preceding analysis, it can furthermore be noted that:

- With respect to the ARVs that have been recommended by WHO for first-line adult treatment in the 2013 consolidated treatment guidelines, market competition is likely to be possible in the vast majority of developing countries. The few exceptions are cases where tenofovir is patented and not covered by licences, and/or where there are patents pending or granted for the combinations of tenofovir with emtricitabine or tenofovir with emtricitabine and efavirenz outside of the licensed territory.\(^{15}\)

- As concerns second-line adult treatment, the situation is more complex, with patents granted in several developing countries for atazanavir, lopinavir and ritonavir. Licences issued for atazanavir are likely to contribute to further market competition.

- Third-line medicines etravirine and raltegravir are widely patented, including in key countries of manufacture, while darunavir appears to be generally off patent; licences are limited for raltegravir and non-existent for etravirine.

- With respect to paediatric treatment, the MPP has negotiated licences relating to most of the patented ARVs recommended by WHO, as well as many of the new ARVs, and is working with partners to develop better-adapted formulations for children of different ages under the Paediatric HIV Treatment Initiative (PHTI).

- As concerns some of the more recent ARVs (such as cobicistat, dolutegravir, elvitegravir, rilpivirine and tenofovir alafenamide), patents have been granted or are pending in several developing countries, including most countries with ARV manufacturing capacity. Licences have now been issued on these ARVs that will enable at least 100 (in some cases many more) developing countries to benefit from competitive procurement. Market competition may be limited in countries unable to benefit from these licences.

On the basis of the available data, the likelihood that market competition can take place for patented ARVs appears to be lowest in certain upper- and lower-middle-income countries outside sub-Saharan Africa. It is highest in low-income countries, least-developed countries, several middle-income countries, and countries in sub-Saharan Africa, where licences are more widely available. However, it is also important to bear in mind that patents in manufacturing countries, such as India, can affect the availability of ARVs in importing countries, even in the absence of local patents in the importing country.

\(^{15}\) Note that these patents or patent applications probably do not cover the combinations with lamivudine instead of emtricitabine. However, for certainty on this issue, a detailed analysis of the claims granted in each country would be required.
## Annex I. Summary table on ARV patents and licences

<table>
<thead>
<tr>
<th>Country</th>
<th>ABC</th>
<th>ATV</th>
<th>COBI</th>
<th>DRV</th>
<th>DTG</th>
<th>EFV</th>
<th>ETV</th>
<th>EVG</th>
<th>LPV</th>
<th>MVC</th>
<th>NVP</th>
<th>RAL</th>
<th>RPV</th>
<th>RTV</th>
<th>TAF</th>
<th>TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Algeria</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Argentina</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Armenia</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Belarus</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Belize</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>China</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Dominica</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Ecuador</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Egypt</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>El Salvador</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Georgia</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Guatemala</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Honduras</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>India</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Indonesia</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Jordan</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
</tbody>
</table>

**Notes:**
- **2nd:** Secondary patents relating to the ARV, including combinations (this entry may combine information on several patents).
- ***:** expected to have expired around August 2013 in most jurisdictions.
- **Diagonal shading:** compulsory licence issued.
- **Light shading:** countries/medicines covered by licences or technology transfer agreements with at least one company.
- **G:** granted patent application; **F:** filed patent application; **-:** no filed or granted patent application; **•:** status of patent application unknown.

16 The information in the table should not be considered a complete and authoritative source of patent information on ARVs. The table provides a snapshot at a particular point in time (30 April 2015) and is based on the information that was available to the Medicines Patent Pool; it includes only some of the patents relating to each ARV.
## Annex I. Summary table on ARV patents and licences (continued)\(^17\)

<table>
<thead>
<tr>
<th>Country</th>
<th>ABC</th>
<th>ATV</th>
<th>COBI</th>
<th>DRV</th>
<th>DTG</th>
<th>EVF</th>
<th>ETV</th>
<th>EVG</th>
<th>LPV</th>
<th>MVC</th>
<th>NVP</th>
<th>RAL</th>
<th>RPV</th>
<th>RTV</th>
<th>TAF</th>
<th>TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyrgyzstan</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>G</td>
</tr>
<tr>
<td>Malaysia</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mexico</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Moldova</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mongolia</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Montenegro</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Morocco</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nigeria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pakistan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Panama</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Paraguay</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Peru</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Philippines</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>South Africa</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thailand</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Turkey</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tunisia</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ukraine</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Venezuela</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vietnam</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

2nd: Secondary patents relating to the ARV, including combinations (this entry may combine information on several patents).

*: expected to have expired around August 2013 in most jurisdictions.

Diagonal shading: compulsory licence issued.

Dark shading: countries/medicines covered by licences or technology transfer agreements with at least one company.

Light shading: countries/medicines covered by licences or technology transfer agreements with at least one company, limited to paediatric formulations.

G: granted patent application; F: filed patent application; : no filed or granted patent application; • status of patent application unknown.

---

\(^17\) The information in the table should not be considered a complete and authoritative source of patent information on ARVs. The table provides a snapshot at a particular point in time (30 April 2015) and is based on the information that was available to the Medicines Patent Pool; it includes only some of the patents relating to each ARV.
## Annex II. Overview of patents and licences relating to selected fixed-dose combinations

<table>
<thead>
<tr>
<th>Combination</th>
<th>Patents and patent applications</th>
<th>Existing voluntary licences</th>
<th>Developing countries where competition may potentially be delayed due to patents/patent applications¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC/3TC</td>
<td>Secondary patents and patent applications on ABC and on ABC/3TC combination.</td>
<td>Licences available for 121 countries (paediatrics) and 69 countries (adult).</td>
<td>Paediatric formulations: Albania*, Brazil, Belarus, Bosnia*, China, Kazakhstan, Jordan, Mexico, Montenegro* and Turkey. Adult formulations: countries outside sub-Saharan Africa; countries that are not least-developed and/or low-income countries.</td>
</tr>
<tr>
<td>ABC/3TC/DTG</td>
<td>Patents and patent applications on DTG granted or pending in several developing countries. Secondary patents on ABC and ABC/3TC granted in several jurisdictions.</td>
<td>Paediatrics licences available for 121 countries; adult licences available for sub-Saharan Africa, least-developed countries, low-income countries, Egypt, India, Indonesia, Philippines, Turkmenistan and Viet Nam. The licence allows sale in countries where no patents are in force.</td>
<td>Countries outside the licensed territories in which there are granted patents.</td>
</tr>
<tr>
<td>ATV/r</td>
<td>Patents on ATV pending in India and granted in a number of other countries. Patents on RTV and RTV tablet formulation also granted in several developing countries.</td>
<td>Licence to the MPP covering 110 countries.</td>
<td>Countries outside the 110 countries covered by the licence with the MPP in which there are granted patents (Argentina, China, Egypt, Indonesia, Malaysia, Mexico, Peru, Philippines, Thailand, Turkey and Ukraine) and additional countries in which there are patents on ritonavir.</td>
</tr>
<tr>
<td>DRV/r</td>
<td>Patents on RTV, RTV tablet formulations and secondary patents on DRV filed or granted in several developing countries.</td>
<td>Commitment not to enforce DRV patents in sub-Saharan Africa, least-developed countries and India for adult formulations and for 128 countries for paediatric formulations.</td>
<td>Albania, Armenia, Azerbaijan, Belarus, Bosnia, Brazil, China, Kazakhstan, Kyrgyzstan, Mexico, Moldova, Montenegro, Philippines, South Africa, Sri Lanka, Tajikistan, Turkey, Turkmenistan, Ukraine and Viet Nam.</td>
</tr>
<tr>
<td>LPV/r</td>
<td>Patents on LPV and on the LPV/r tablet formulation have been granted in several jurisdictions, but not in India (a key country of manufacture). In November 2014, paediatrics licence granted to the MPP covering 102 countries, which also allows sales in countries in which LPV/r is not patented.</td>
<td></td>
<td>Countries outside the 102 countries covered by the paediatrics licence with the MPP in which there are granted patents (Albania, Argentina, Belarus, Bosnia, China, Colombia, Kazakhstan, Mexico, Montenegro, Philippines, Turkey, Ukraine) and all other countries with granted patents or pending applications relevant to the adult formulation.</td>
</tr>
</tbody>
</table>

¹ Pending applications are marked with an asterix.
### Annex II. Overview of patents and licences relating to selected fixed-dose combinations

<table>
<thead>
<tr>
<th><strong>TAF/FTC/DTG</strong></th>
<th>Patents and patent applications on both TAF and DTG granted or pending in several developing countries.</th>
<th>MPP licence agreements on TAF and DTG adult and paediatric formulations cover respectively 112, 73 and 121 countries. The DTG licence allows sale in countries where DTG is not patented.</th>
<th>Countries outside the TAF licensed territory. In addition, countries outside the DTG licensed territory in which DTG is patented.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TDF/FTC</strong></td>
<td>There are patents or patent applications on TDF/FTC and TDF/FTC/EFV, which may not cover TDF/3TC or TDF/3TC/EFV, depending on the exact text of those patents or patent applications. TDF patents have been granted in China, Indonesia and Mexico.</td>
<td>Licences on TDF/FTC cover 112 countries and were issued to many ARV manufacturers in India and South Africa.</td>
<td>For TDF/FTC: Argentina*, Azerbaijan, Belarus, Brazil*, China, Mexico, Turkey, Ukraine and Venezuela*.</td>
</tr>
<tr>
<td><strong>TDF/FTC</strong></td>
<td>TDF patents granted in China, Indonesia and Mexico. Patents and patent applications on DTG granted or pending in several developing countries.</td>
<td>Licences for TDF/FTC covering 112 countries and issued to many manufacturers in China, India and South Africa. Paediatrics licence for DTG covering 121 countries; adult DTG licence covering sub-Saharan Africa, least-developed countries, low-income countries, Egypt, India, Indonesia, Philippines, Turkmenistan and Viet Nam. The licence allows sale in countries where no patents are in force.</td>
<td>Countries outside the DTG adult licensed territories in which DTG or TDF patent is granted (e.g. Algeria, China, Colombia, EAPO member countries, Mexico, Mongolia, Morocco, Turkey and Ukraine).</td>
</tr>
<tr>
<td><strong>TDF/FTC/EFV</strong></td>
<td>There are patents or patent applications on TDF/FTC and TDF/FTC/EFV, which may not cover TDF/3TC or TDF/3TC/EFV, depending on the exact text of those patents or patent applications. TDF patents have been granted in China, Indonesia and Mexico, and EFV patents have expired in most developing countries with few exceptions (e.g. Ukraine).</td>
<td>Licences on TDF/FTC cover 112 countries and were issued to many ARV manufacturers in India and South Africa.</td>
<td>For TDF/FTC/EFV: Argentina*, Azerbaijan, Belarus, Brazil*, China, Mexico, Turkey, Ukraine and Venezuela*.</td>
</tr>
<tr>
<td><strong>TDF/FTC/EVG/Cobi</strong></td>
<td>Patents and patent applications on Cobi, EVG and TDF/FTC in several developing countries.</td>
<td>Licences available to various manufacturers for up to 109 countries.</td>
<td>Countries outside the 109 countries included in the voluntary licences.</td>
</tr>
<tr>
<td><strong>TDF/FTC/RPV</strong></td>
<td>Patents on RPV, TDF/FTC and TDF/FTC/RPV in several developing countries.</td>
<td>Licences available to various manufacturers for 112 countries.</td>
<td>Countries outside the 112 countries included in the voluntary licences.</td>
</tr>
</tbody>
</table>
Annex III. Licensing policies by ARV

For most licence agreements, only basic information is known, such as the name of the licensees, the geographical scope and, in some cases, the royalties payable to the licensors. Other terms and conditions are generally kept confidential, thus preventing a detailed analysis. However, it is important to note that, in addition to the terms mentioned above, many other provisions may have an important impact on access, market competition and the development of adapted formulations, including fixed-dose combinations.

<table>
<thead>
<tr>
<th>ARV</th>
<th>Number of licensees</th>
<th>Geographical scope</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir</td>
<td>Several</td>
<td>Paediatrics: 121 Adults: 69</td>
<td>Paediatrics: licensed through the MPP (full text of licence on MPP website)</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>Aurobindo, Cipla, Desano, and Emcure (through the MPP)</td>
<td>110 countries, plus possibility of selling outside licensed countries under certain circumstances</td>
<td>Licensed to the MPP in December 2013 Bilateral agreements; detailed terms and conditions not known In the form of a technology transfer agreement</td>
</tr>
<tr>
<td></td>
<td>Three bilateral licensees</td>
<td>Sub-Saharan Africa and India: 49 countries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Farmanguinhos</td>
<td>Brazil</td>
<td></td>
</tr>
<tr>
<td>Cobicistat</td>
<td>Multiple licensees (including Aurobindo, Emcure, Hetero, Laurus, Mylan, Ranbaxy, Shasun, Strides)</td>
<td>Non-exclusive: 103 countries Semi-exclusive: 9 countries</td>
<td>103 countries through the MPP (full text of licence on MPP website); 9 countries on semi-exclusive basis to one licensee</td>
</tr>
<tr>
<td>Darunavir</td>
<td>Unknown</td>
<td>Sub-Saharan Africa, India and least-developed countries for adult formulations and 128 countries for paediatric formulations.</td>
<td>Commitment not to enforce</td>
</tr>
<tr>
<td>Dolutegravir</td>
<td>Multiple licensees (including Cipla, Desano, Emcure, Hetero, Laurus, Micro Labs and Mylan – through the MPP)</td>
<td>Paediatrics: 121 countries Adults: sub-Saharan Africa, least-developed countries, low-income countries, Egypt, India, Indonesia, Philippines, Turkmenistan, Viet Nam and countries with no granted patents on DTG</td>
<td>Licensed to the MPP in April 2014</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Several</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>Elvitegravir</td>
<td>Multiple licensees (including Aurobindo, Emcure, Hetero, Laurus, Mylan, Ranbaxy, Shasun, Strides)</td>
<td>Non-exclusive: 100 countries Semi-exclusive: 9 countries</td>
<td>100 countries through the MPP (full text of licence on MPP website); other countries on semi-exclusive basis</td>
</tr>
<tr>
<td>Etravirine</td>
<td>None</td>
<td>-</td>
<td>There are packaging and distribution agreements with at least one company</td>
</tr>
</tbody>
</table>

18 The exceptions are the licences negotiated by the MPP.
## Annex III. Licensing policies by ARV

<table>
<thead>
<tr>
<th>Drug</th>
<th>Licensing Status</th>
<th>Paediatrics: 102 countries and countries with no patents on LPV/r</th>
<th>Paediatrics: licensed through the MPP (full text of licence on MPP website)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lopinavir</strong></td>
<td>Licensed to the MPP for paediatrics;</td>
<td>No licences for adult formulations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>process for sub-licensing ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maraviroc</strong></td>
<td>None</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Raltegravir</strong></td>
<td>Licence to the MPP for paediatrics;</td>
<td>Paediatrics: 92 countries</td>
<td>Paediatrics: licensed through the MPP (full text of licence on MPP website)</td>
</tr>
<tr>
<td></td>
<td>process of sub-licensing ongoing</td>
<td>Adult formulations: Sub-Saharan Africa and low-income countries</td>
<td>Bilateral licences; detailed terms and conditions not known.</td>
</tr>
<tr>
<td></td>
<td>Two for adult formulations: Emcure and Mylan</td>
<td>Brazil</td>
<td>In the form of a technology transfer agreement</td>
</tr>
<tr>
<td></td>
<td>One</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rilpivirine</strong></td>
<td>Five (Aspen, Emcure, Hetero, Mylan and Strides Arcolab)</td>
<td>112 countries</td>
<td>Bilateral licences; detailed terms and conditions not known.</td>
</tr>
<tr>
<td><strong>Ritonavir</strong></td>
<td>Licensed to the MPP for paediatrics;</td>
<td>Paediatrics: 102 countries</td>
<td>Full text of licence on MPP website</td>
</tr>
<tr>
<td></td>
<td>process for sub-licensing ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tenofovir</strong></td>
<td>Multiple licensees, some through the</td>
<td>112 countries</td>
<td>Licensed through the MPP (full text of licence on MPP website)</td>
</tr>
<tr>
<td>alafenamide</td>
<td>MPP, others bilaterally</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tenofovir</strong></td>
<td>Multiple licensees, some through the</td>
<td>112 countries</td>
<td>Licensed through the MPP (full text of licence on MPP website)</td>
</tr>
<tr>
<td>disoproxil</td>
<td>MPP, others bilaterally</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fumarate</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>